Arcturus therapeutics presents new clinical data at 47th annual european cystic fibrosis conference

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global messenger rna medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented phase 1 results in healthy volunteers and phase 1b interim data in people with cf for arct-032, an inhaled investigational mrna therapeutic, at the 47th european cystic fibrosis conference i.
ARCT Ratings Summary
ARCT Quant Ranking